Dr. Claudia Cardone
ESMO is doing a lot for young oncologists
Dr. Claudia Cardone, Università Vanvitelli in Naples, Italy, is currently a research fellow at the Medical University of Vienna to investigate biomarkers in CRC. She also describes what ESMO young oncologists can do for “youngsters”.
Video Contents00:00 Axl might be a new biomarker for cetuximab resistance in metastatic colorectal cancer 04:00 What ESMO Young Oncologists are doing to advance the career of young doctors in the field 05:48 The TRIBE-2 trial (upfront use of FOLFOXIRI in metastatic colorectal cancer patients compared with sequential use of oxaliplatin-based and irinotecan-based doublets)
Source: ESMO 2018 Congress
Cardone C et al., AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Abstract #96P
Cremolini C et al., TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts). Abstract #LBA2
More from this topic: